S&P 500   3,362.83 (-0.31%)
DOW   27,837.87 (-0.21%)
QQQ   271.62 (-0.32%)
AAPL   456.58 (-0.75%)
MSFT   208.22 (-0.23%)
FB   260.74 (-0.21%)
GOOGL   1,506.66 (-0.66%)
AMZN   3,135.00 (-0.82%)
NVDA   459.71 (+0.43%)
CGC   17.17 (-0.87%)
BABA   252.85 (-0.34%)
TSLA   1,642.77 (+1.34%)
GE   6.67 (+1.06%)
MU   45.69 (-0.98%)
AMD   81.20 (-0.78%)
T   30.00 (+0.30%)
F   7.05 (+0.28%)
ACB   10.70 (+5.11%)
GILD   68.61 (+0.63%)
NFLX   481.56 (+0.05%)
DIS   130.39 (-0.44%)
BAC   26.40 (+0.19%)
BA   177.47 (+1.57%)
S&P 500   3,362.83 (-0.31%)
DOW   27,837.87 (-0.21%)
QQQ   271.62 (-0.32%)
AAPL   456.58 (-0.75%)
MSFT   208.22 (-0.23%)
FB   260.74 (-0.21%)
GOOGL   1,506.66 (-0.66%)
AMZN   3,135.00 (-0.82%)
NVDA   459.71 (+0.43%)
CGC   17.17 (-0.87%)
BABA   252.85 (-0.34%)
TSLA   1,642.77 (+1.34%)
GE   6.67 (+1.06%)
MU   45.69 (-0.98%)
AMD   81.20 (-0.78%)
T   30.00 (+0.30%)
F   7.05 (+0.28%)
ACB   10.70 (+5.11%)
GILD   68.61 (+0.63%)
NFLX   481.56 (+0.05%)
DIS   130.39 (-0.44%)
BAC   26.40 (+0.19%)
BA   177.47 (+1.57%)
S&P 500   3,362.83 (-0.31%)
DOW   27,837.87 (-0.21%)
QQQ   271.62 (-0.32%)
AAPL   456.58 (-0.75%)
MSFT   208.22 (-0.23%)
FB   260.74 (-0.21%)
GOOGL   1,506.66 (-0.66%)
AMZN   3,135.00 (-0.82%)
NVDA   459.71 (+0.43%)
CGC   17.17 (-0.87%)
BABA   252.85 (-0.34%)
TSLA   1,642.77 (+1.34%)
GE   6.67 (+1.06%)
MU   45.69 (-0.98%)
AMD   81.20 (-0.78%)
T   30.00 (+0.30%)
F   7.05 (+0.28%)
ACB   10.70 (+5.11%)
GILD   68.61 (+0.63%)
NFLX   481.56 (+0.05%)
DIS   130.39 (-0.44%)
BAC   26.40 (+0.19%)
BA   177.47 (+1.57%)
S&P 500   3,362.83 (-0.31%)
DOW   27,837.87 (-0.21%)
QQQ   271.62 (-0.32%)
AAPL   456.58 (-0.75%)
MSFT   208.22 (-0.23%)
FB   260.74 (-0.21%)
GOOGL   1,506.66 (-0.66%)
AMZN   3,135.00 (-0.82%)
NVDA   459.71 (+0.43%)
CGC   17.17 (-0.87%)
BABA   252.85 (-0.34%)
TSLA   1,642.77 (+1.34%)
GE   6.67 (+1.06%)
MU   45.69 (-0.98%)
AMD   81.20 (-0.78%)
T   30.00 (+0.30%)
F   7.05 (+0.28%)
ACB   10.70 (+5.11%)
GILD   68.61 (+0.63%)
NFLX   481.56 (+0.05%)
DIS   130.39 (-0.44%)
BAC   26.40 (+0.19%)
BA   177.47 (+1.57%)
Log in

NASDAQ:BLPHBellerophon Therapeutics Stock Price, Forecast & News

$12.08
-0.17 (-1.39 %)
(As of 08/14/2020 03:42 PM ET)
Add
Compare
Today's Range
$11.89
Now: $12.08
$12.08
50-Day Range
$12.06
MA: $12.88
$13.71
52-Week Range
$3.19
Now: $12.08
$26.00
Volume992 shs
Average Volume505,177 shs
Market Capitalization$114.74 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.7
Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company, which focuses on developing innovative products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The company engages in two programs including INOpulse and BCM. INOpulse is based on proprietary pulsatile nitric oxide delivery device. BCM is based on placebo-controlled clinical trial designed to support CE mark registration in the European Union. Bellerophon Therapeutics was founded in 2009 and is headquartered in Warren, NJ.
Read More
Bellerophon Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.63 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BLPH
CUSIPN/A
Phone908-574-4770

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$5.62 per share

Profitability

Net Income$-13,270,000.00

Miscellaneous

Employees17
Market Cap$114.74 million
Next Earnings Date11/4/2020 (Estimated)
OptionableNot Optionable
$12.08
-0.17 (-1.39 %)
(As of 08/14/2020 03:42 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BLPH News and Ratings via Email

Sign-up to receive the latest news and ratings for BLPH and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Bellerophon Therapeutics (NASDAQ:BLPH) Frequently Asked Questions

How has Bellerophon Therapeutics' stock been impacted by COVID-19?

Bellerophon Therapeutics' stock was trading at $6.29 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, BLPH stock has increased by 92.1% and is now trading at $12.08.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Bellerophon Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bellerophon Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Bellerophon Therapeutics
.

When is Bellerophon Therapeutics' next earnings date?

Bellerophon Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Bellerophon Therapeutics
.

How were Bellerophon Therapeutics' earnings last quarter?

Bellerophon Therapeutics Inc (NASDAQ:BLPH) announced its quarterly earnings results on Wednesday, August, 5th. The biotechnology company reported ($0.51) EPS for the quarter, topping analysts' consensus estimates of ($0.72) by $0.21.
View Bellerophon Therapeutics' earnings history
.

When did Bellerophon Therapeutics' stock split? How did Bellerophon Therapeutics' stock split work?

Shares of Bellerophon Therapeutics reverse split on Monday, February 10th 2020. The 1-15 reverse split was announced on Friday, February 7th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 7th 2020. An investor that had 100 shares of Bellerophon Therapeutics stock prior to the reverse split would have 7 shares after the split.

What price target have analysts set for BLPH?

4 analysts have issued 1-year target prices for Bellerophon Therapeutics' shares. Their forecasts range from $19.00 to $35.00. On average, they anticipate Bellerophon Therapeutics' share price to reach $28.50 in the next year. This suggests a possible upside of 135.9% from the stock's current price.
View analysts' price targets for Bellerophon Therapeutics
.

Has Bellerophon Therapeutics been receiving favorable news coverage?

News stories about BLPH stock have been trending extremely negative recently, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Bellerophon Therapeutics earned a coverage optimism score of -4.0 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days.
View the latest news about Bellerophon Therapeutics
.

Are investors shorting Bellerophon Therapeutics?

Bellerophon Therapeutics saw a increase in short interest in June. As of June 15th, there was short interest totaling 380,700 shares, an increase of 245.5% from the May 31st total of 110,200 shares. Based on an average daily trading volume, of 451,600 shares, the days-to-cover ratio is currently 0.8 days. Approximately 7.1% of the shares of the company are sold short.
View Bellerophon Therapeutics' Short Interest
.

Who are some of Bellerophon Therapeutics' key competitors?

What other stocks do shareholders of Bellerophon Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bellerophon Therapeutics investors own include Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Chesapeake Energy (CHKAQ), Chesapeake Energy (CHKAQ), Novavax (NVAX), Verastem (VSTM), Gilead Sciences (GILD), SCYNEXIS (SCYX), AVEO Pharmaceuticals (AVEO) and Co-Diagnostics (CODX).

Who are Bellerophon Therapeutics' key executives?

Bellerophon Therapeutics' management team includes the following people:
  • Fabian Tenenbaum, Chief Executive Officer & Director
  • Assaf Korner, Chief Financial Officer & Secretary
  • Amy Edmonds, VP-Clinical Operations & Administration
  • Martin Dekker, Vice President-Engineering & Manufacturing
  • Peter Fernandes, Chief Regulatory & Safety Officer

When did Bellerophon Therapeutics IPO?

(BLPH) raised $60 million in an initial public offering (IPO) on Friday, February 13th 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. Leerink Partners and Cowen and Company served as the underwriters for the IPO and FBR and SunTrust Robinson Humphrey were co-managers.

What is Bellerophon Therapeutics' stock symbol?

Bellerophon Therapeutics trades on the NASDAQ under the ticker symbol "BLPH."

Who are Bellerophon Therapeutics' major shareholders?

Bellerophon Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Telemetry Investments L.L.C. (1.32%), DAVENPORT & Co LLC (1.13%), Tocqueville Asset Management L.P. (0.27%), New York State Common Retirement Fund (0.08%) and American International Group Inc. (0.02%). Company insiders that own Bellerophon Therapeutics stock include Associates Iv L P Venrock, Fabian Tenenbaum, Jonathan M Peacock, Naseem Amin and Theodore T Wang.
View institutional ownership trends for Bellerophon Therapeutics
.

Which institutional investors are buying Bellerophon Therapeutics stock?

BLPH stock was bought by a variety of institutional investors in the last quarter, including DAVENPORT & Co LLC, Telemetry Investments L.L.C., Tocqueville Asset Management L.P., New York State Common Retirement Fund, and American International Group Inc.. Company insiders that have bought Bellerophon Therapeutics stock in the last two years include Associates Iv L P Venrock, Fabian Tenenbaum, Jonathan M Peacock, Naseem Amin, and Theodore T Wang.
View insider buying and selling activity for Bellerophon Therapeutics
.

How do I buy shares of Bellerophon Therapeutics?

Shares of BLPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Bellerophon Therapeutics' stock price today?

One share of BLPH stock can currently be purchased for approximately $12.08.

How big of a company is Bellerophon Therapeutics?

Bellerophon Therapeutics has a market capitalization of $114.74 million. The biotechnology company earns $-13,270,000.00 in net income (profit) each year or ($2.95) on an earnings per share basis. Bellerophon Therapeutics employs 17 workers across the globe.

What is Bellerophon Therapeutics' official website?

The official website for Bellerophon Therapeutics is www.bellerophon.com.

How can I contact Bellerophon Therapeutics?

Bellerophon Therapeutics' mailing address is 184 LIBERTY CORNER ROAD SUITE 302, WARREN NJ, 07059. The biotechnology company can be reached via phone at 908-574-4770 or via email at [email protected]

This page was last updated on 8/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.